Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.

Saukkonen K, Hagström J, Mustonen H, Lehtinen L, Carpen O, Andersson LC, Seppänen H, Haglund C.

Tumour Biol. 2018 Mar;40(3):1010428318761494. doi: 10.1177/1010428318761494.

PMID:
29542402
2.

Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma.

Arpalahti L, Saukkonen K, Hagström J, Mustonen H, Seppänen H, Haglund C, Holmberg CI.

Tumour Biol. 2017 Jun;39(6):1010428317710411. doi: 10.1177/1010428317710411.

PMID:
28653876
3.

Case 8-2016: A Man with Recurrent Fevers, Hypoxemia, and Lung Infiltrates.

Saukkonen K, Sharma A.

N Engl J Med. 2016 Jul 28;375(4):392-3. doi: 10.1056/NEJMc1604864. No abstract available.

PMID:
27464217
4.

PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.

Saukkonen K, Hagström J, Mustonen H, Juuti A, Nordling S, Kallio P, Alitalo K, Seppänen H, Haglund C.

BMC Cancer. 2016 Jul 13;16:472. doi: 10.1186/s12885-016-2497-5.

5.

CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 18-2016. A 52-Year-Old Woman with a Pleural Effusion.

Ray A, Masch WR, Saukkonen K, Harrison BT.

N Engl J Med. 2016 Jun 16;374(24):2378-87. doi: 10.1056/NEJMcpc1600612. No abstract available. Erratum in: N Engl J Med. 2016 Jul 28;375(4):398.

PMID:
27305196
6.

CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 8-2016. A 71-Year-Old Man with Recurrent Fevers, Hypoxemia, and Lung Infiltrates.

Saukkonen K, Sharma A, Mark EJ.

N Engl J Med. 2016 Mar 17;374(11):1077-85. doi: 10.1056/NEJMcpc1505680. No abstract available.

PMID:
26981938
7.

Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.

Saukkonen K, Hagström J, Mustonen H, Juuti A, Nordling S, Fermér C, Nilsson O, Seppänen H, Haglund C.

PLoS One. 2015 Jun 8;10(6):e0129012. doi: 10.1371/journal.pone.0129012. eCollection 2015.

8.

Case 9-2014: A woman with increasing dyspnea.

Saukkonen K.

N Engl J Med. 2014 Jul 24;371(4):388-9. doi: 10.1056/NEJMc1404715. No abstract available.

PMID:
25054729
9.

Case records of the Massachusetts General Hospital. Case 9-2014. A 34-year-old woman with increasing dyspnea.

Saukkonen K, Tan TC, Sharma A, Channick RN, Murali MR, Zukerberg LR.

N Engl J Med. 2014 Mar 20;370(12):1149-57. doi: 10.1056/NEJMcpc1305992. No abstract available. Erratum in: N Engl J Med. 2014 Jun 5;370(23):2253.

PMID:
24645948
10.

Heme oxygenase 1 polymorphisms and plasma concentrations in critically ill patients.

Saukkonen K, Lakkisto P, Kaunisto MA, Varpula M, Voipio-Pulkki LM, Varpula T, Pettilä V, Pulkki K.

Shock. 2010 Dec;34(6):558-64. doi: 10.1097/SHK.0b013e3181e14de9.

PMID:
20386498
11.

Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock.

Saukkonen K, Lakkisto P, Pettilä V, Varpula M, Karlsson S, Ruokonen E, Pulkki K; Finnsepsis Study Group.

Clin Chem. 2008 Jun;54(6):1000-7. doi: 10.1373/clinchem.2007.101030. Epub 2008 Apr 17.

12.

Association of cell-free plasma DNA with hospital mortality and organ dysfunction in intensive care unit patients.

Saukkonen K, Lakkisto P, Varpula M, Varpula T, Voipio-Pulkki LM, Pettilä V, Pulkki K.

Intensive Care Med. 2007 Sep;33(9):1624-7. Epub 2007 May 31.

PMID:
17541553
13.

The effect of emergency department delay on outcome in critically ill medical patients: evaluation using hospital mortality and quality of life at 6 months.

Saukkonen KA, Varpula M, Räsänen P, Roine RP, Voipio-Pulkki LM, Pettilä V.

J Intern Med. 2006 Dec;260(6):586-91.

14.

Hemodynamic variables related to outcome in septic shock.

Varpula M, Tallgren M, Saukkonen K, Voipio-Pulkki LM, Pettilä V.

Intensive Care Med. 2005 Aug;31(8):1066-71. Epub 2005 Jun 23.

PMID:
15973520
15.

Tissue-specific promoters for cancer gene therapy.

Saukkonen K, Hemminki A.

Expert Opin Biol Ther. 2004 May;4(5):683-96. Review.

PMID:
15155160
16.

Cyclooxygenase-2 and gastric carcinogenesis.

Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, Haglund C, Van Lanschot JJ, Offerhaus GJ, Ristimaki A.

APMIS. 2003 Oct;111(10):915-25. Review.

PMID:
14616542
17.

Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice.

Saukkonen K, Tomasetto C, Narko K, Rio MC, Ristimäki A.

Cancer Res. 2003 Jun 15;63(12):3032-6.

18.

[Cyclo-oxygenase 2 in cancer].

Saukkonen K, Narko K, Ristimäki A.

Duodecim. 1999;115(8):855-6. Finnish. No abstract available.

PMID:
11859518
19.

Cyclooxygenase-2 expression during carcinogenesis in the human stomach.

van Rees BP, Saukkonen K, Ristimäki A, Polkowski W, Tytgat GN, Drillenburg P, Offerhaus GJ.

J Pathol. 2002 Feb;196(2):171-9.

PMID:
11793368
20.

Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma.

Saukkonen K, Nieminen O, van Rees B, Vilkki S, Härkönen M, Juhola M, Mecklin JP, Sipponen P, Ristimäki A.

Clin Cancer Res. 2001 Jul;7(7):1923-31.

21.

Regulated expression of prostaglandin E(2) receptors EP2 and EP4 in human ovarian granulosa-luteal cells.

Narko K, Saukkonen K, Ketola I, Bützow R, Heikinheimo M, Ristimäki A.

J Clin Endocrinol Metab. 2001 Apr;86(4):1765-8.

PMID:
11297615
22.

Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder.

Ristimäki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C.

Am J Pathol. 2001 Mar;158(3):849-53.

23.

Expression of cyclooxygenase-2 and prostanoid receptors by human myometrium.

Erkinheimo TL, Saukkonen K, Narko K, Jalkanen J, Ylikorkala O, Ristimäki A.

J Clin Endocrinol Metab. 2000 Sep;85(9):3468-75.

PMID:
10999850
24.

Expression of cyclooxygenase-2 in human lung carcinoma.

Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimäki A.

Cancer Res. 1998 Nov 15;58(22):4997-5001.

26.

Pertussis toxin has eukaryotic-like carbohydrate recognition domains.

Saukkonen K, Burnette WN, Mar VL, Masure HR, Tuomanen EI.

Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):118-22.

27.

Integrin-mediated localization of Bordetella pertussis within macrophages: role in pulmonary colonization.

Saukkonen K, Cabellos C, Burroughs M, Prasad S, Tuomanen E.

J Exp Med. 1991 May 1;173(5):1143-9.

28.

Recognition of a bacterial adhesion by an integrin: macrophage CR3 (alpha M beta 2, CD11b/CD18) binds filamentous hemagglutinin of Bordetella pertussis.

Relman D, Tuomanen E, Falkow S, Golenbock DT, Saukkonen K, Wright SD.

Cell. 1990 Jun 29;61(7):1375-82.

PMID:
2364431
29.

The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis.

Saukkonen K, Sande S, Cioffe C, Wolpe S, Sherry B, Cerami A, Tuomanen E.

J Exp Med. 1990 Feb 1;171(2):439-48.

30.

The nature of cell wall-derived inflammatory components of pneumococci.

Tomasz A, Saukkonen K.

Pediatr Infect Dis J. 1989 Dec;8(12):902-3. No abstract available.

PMID:
2626297
32.
33.

Beneficial effects of a specific leukotriene receptor antagonist in splanchnic artery occlusion shock.

Lento PH, Saukkonen K, Aoki N, Lefer AM, Slivjak MJ, Smith EF 3rd.

Eur J Pharmacol. 1989 Jun 20;165(2-3):241-9.

PMID:
2550251
34.

Monoclonal antibodies to the rough lipopolysaccharide of Neisseria meningitidis protect infant rats from meningococcal infection.

Saukkonen K, Leinonen M, Käyhty H, Abdillahi H, Poolman JT.

J Infect Dis. 1988 Jul;158(1):209-12. No abstract available.

PMID:
3134492
35.
36.

Experimental meningococcal meningitis in the infant rat.

Saukkonen K.

Microb Pathog. 1988 Mar;4(3):203-11.

PMID:
3193872
38.

Antibodies to the capsular polysaccharide of Neisseria meningitidis group B or E. coli K1 bind to the brains of infant rats in vitro but not in vivo.

Saukkonen K, Haltia M, Frosch M, Bitter-Süerman D, Leinonen M.

Microb Pathog. 1986 Feb;1(1):101-5.

PMID:
3150023
39.

A whole-blood lymphocyte stimulation test for the diagnosis of human tularemia.

Syrjälä H, Herva E, Ilonen J, Saukkonen K, Salminen A.

J Infect Dis. 1984 Dec;150(6):912-5.

PMID:
6501932

Supplemental Content

Loading ...
Support Center